Lutetium-177: PSMA Guided Treatment | #ProstateCancer | #MarkScholzMD | #PCRI

Lutetium-177 was recently FDA-approved in the United States for men with hormone-resistant PSMA-positive prostate cancer who have already been administered chemotherapy (regardless if the entire regimen was completed). Here, medical oncologist Mark Scholz, MD, discusses who qualifies for Lutetium-177, why it is not available to men with earlier-stage disease, and how to monitor whether or not the treatment was effective after it is administered.

0:07 What is a PSMA PET scan and its associated treatment, Lutetium-177?

1:59 Should a PSMA PET scan be performed after Lutetium-177 to see if the treatment worked?

2:50 What is the success rate of Lutetium-177?

3:54 If lutetium-177 works well, why is it not available in earlier stages of the disease?

5:49 How does hormone therapy influence PSMA PET scan and lutetium 177. Can they be used together?

7:38 After Lutetium-177, when should a patient get a scan to see if it was effective?

9:20 How do you interpret PSA after a patient receives Lutetium-177?

Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org

To learn more about prostate cancer visit http://www.pcri.org

Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: https://pcri.org/join

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.

The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.

#ProstateCancer #MarkScholzMD #PCRI